Salute e Benessere

Vistin Pharma ASA: Invitation to Q1 2025 conference call

Vistin Pharma ASA (VISTN) will release its first quarter results on Friday 25th of April 2025. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day at 08:30 CET. There will be a Q&A session following the management discussion.The conference call will be held in English.The first quarter conference call will be available via web and audio through the following access points: Webcast:https://edge.media-server.com/mmc/p/9g56ohth ...
Nasdaq GlobeNewswire
15/04/2025

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Company Announcement Net sales of DARZALEX ®in the first quarter of 2025 totaled USD 3,237 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.)COPENHAGEN, Denmark; April 15, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj , sold under the...
Nasdaq GlobeNewswire
15/04/2025

Invitation: Sobi's Q1 report

The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call. The presentation can be followed livehere or afterwards on sobi.com. The slides will be made available onsobi.combefore the conference call. To participate in the conference call, please use the following dial-in details:Sweden : +46 8 5051 0031United Kingdom : +44 207 107 06 13United States : +1 631 570 56 13 For other countries, please...
PR Newswire
15/04/2025

Vantage Foundation Visits SOS Children's Villages Portugal: Addressing Neglect…

In Portugal, every 10 minutes, a child grows up without the support they need to thrive—many facing neglect that can span generations. Because neglect is less visible than other forms of harm, it often escapes intervention, leaving children to endure silent, long-lasting trauma. SOS Children's Villages Portugal works to break this cycle through prevention, protection, and advocacy, ensuring no child is left behind. InPortugal, every 10 minutes, a child grows up without the support they need...
PR Newswire
15/04/2025

Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets

/ XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, will host an in-person and virtual R&D Day today, Tuesday, April 15, 2025 from 10:00 AM to 12:00 PM ET at the Intercontinental New York Barclay hotel. To attend the event or participate virtually, please registerhere. The event will provide an update on Oculis' portfolio of three innovative...
Nasdaq GlobeNewswire
15/04/2025

Meribel Pharma Solutions launches with big ambitions to elevate pharma services…

Meribel Pharma Solutions is headed up by an experienced team including CEO, Bruce Vielle, formerly President, CEO of Synerlab, and COO, Steve Leonard, who joins the firm from Integra Life Sciences where he was Corporate VP, Global Operations & Supply Chain. Prior to that, he was SVP, Head of Global Operations at Catalent. Meribel Pharma Solutions is headed up by an experienced team including CEO,Bruce Vielle, formerly President, CEO of Synerlab, and COO,Steve Leonard, who joins the firm...
PR Newswire
15/04/2025

Astraveus Strengthens Leadership Team and Board

David Newble has also held multiple C-Suite roles across various life sciences technology companies, including the founding of protein analytics company Fluidic Sciences. He is a former CEO of SPT Labtech, and TAP Biosystems, where he played a pivotal role in the development of the Ambr® bioreactor portfolio prior to the Company's acquisition by Sartorius. David Newblehas also held multiple C-Suite roles across various life sciences technology companies, including the founding of protein...
PR Newswire
15/04/2025

Open nominations for the BIAL Award in Biomedicine 2025 with an increased amount…

An independent Jury will choose the winning work among the high-quality empirical research papers in biomedicine published from 2016 onwards in peer-reviewed journals. The articles should be nominated by Scientific Societies, Heads of Medical Schools, Heads of Biomedical Research Institutes, Heads of prestigious Academies, Members of the Jury, Members of the Scientific Board of the BIAL Foundation, and previous winners of the BIAL Award. Self-nominations are not allowed. An independentJury...
PR Newswire
15/04/2025

Statutory negotiations at Orion's R&D unit in Turku, Finland have been concluded

ORION CORPORATIONPRESS RELEASE15 April 2025 at 10.00 EEST Statutory negotiations at Orion's R&D unit in Turku, Finland have been concludedOrion Corporation announced in a press release on 10 March 2025 that the company is establishing a new research and development centre in Cambridge, UK with a focus on biological medicines. As the company's plan is to develop biological and large-molecule therapies in Cambridge, a statutory negotiation process commenced on 7...
Nasdaq GlobeNewswire
15/04/2025

NEC Laboratories Europe and Data-Driven.AI enhance AI medical diagnosis to…

Giampaolo Pileggi, Project Manager in Biomedical AI at NEC Laboratories Europe, explains, "The human body is incredibly complex, its organ systems working in harmony to keep us healthy. Over time, a minor issue with one system can quickly become serious and affect others." He adds, "Doctors can greatly benefit from AI systems that can uncover hidden correlations in medical data, detecting even the slightest anomalies that may indicate an imbalance in the body. These advanced tools…
PR Newswire
15/04/2025

Leading Australian private hospital chooses Sectra's enterprise imaging solution…

He continues: "Sectra understands the current strain on the Australian healthcare market and designs their solutions to meet the clinical and financial needs of an organization while offering applications and support for future workflow improvement. Sectra also offers opportunities to utilize AI integration to improve the clinicians' experience and confidence in outcomes." He continues: "Sectra understands the current strain on the Australian healthcare market and designs their…
PR Newswire
15/04/2025

Implantica publishes Annual Report 2024

For further information, please contact:Nicole Pehrsson, Chief Corporate Affairs OfficerTelephone (CH): +41 (0)79 335 09 [email protected] For further information, please contact: Nicole Pehrsson, Chief Corporate Affairs Officer Telephone (CH): +41 (0)79 335 09 [email protected] Implantica is listed on Nasdaq First North Premier Growth Market inStockholm. The company's Certified Adviser is FNCA Sweden AB,[email protected] The information was sent...
PR Newswire
15/04/2025

Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Sweden

PSMA-PET imaging represents a significant advancement in prostate cancer management, largely replacing conventional imaging methods (bone scan, CT[4] scan) as the standard of care after initial diagnosis and biochemical recurrence (BCR). Global guidelines highlight the superior accuracy of PSMA-PET for the staging of primary disease and evaluation of BCR/biochemical persistence (BCP)[5]. Illuccix® PSMA-PET will help fulfil a critical unmet need by facilitating access to timely and effective…
PR Newswire
15/04/2025

Norgine strengthens rare disease portfolio with acquisition of Theravia

PARIS, April 15, 2025 /PRNewswire/ -- Norgine and Theravia announced today that they have entered into a definitive agreement under which Norgine will acquire Theravia, an international pharmaceutical company specialising in cutting-edge treatments for patients with rare and debilitating conditions. PARIS , April 15, 2025 /PRNewswire/ --Norgine and Theraviaannounced today that they have entered into a definitive agreement under which Norgine will acquire Theravia, an international...
PR Newswire
15/04/2025

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation…

Partnership bolsters Boehringer's autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need. The agreement focuses on further research and development of a novel, first-in-class bispecific compound for T cell mediated targeted depletion of specific B cells to address autoimmune and inflammatory diseases. The candidate compound has the potential to reach patients with autoimmune...
Nasdaq GlobeNewswire
15/04/2025

Westbourne River Partners letter to Biotest AG

Cc: Supervisory Board Cc: Supervisory Board Dear Peter, We are writing to you on behalf of Westbourne River Event Master Fund ("Westbourne River" or "we"), the largest minority shareholder in Biotest AG ("Biotest" or the "Company"), with respect to the delisting offer made by Grifols S.A. ("Grifols") to shareholders of the Company. We are deeply concerned about the decision of the management board to support the delisting, and we ask that the…
PR Newswire
15/04/2025

Narwal Unveils Freo Z10 Ultra, Unlocking a New Level of AI-enhanced Deep…

Get Flexible Cleaning in Real-Time with AI-enhanced Adaptive Cleaning Strategies Get Flexible Cleaning in Real-Time with AI-enhanced Adaptive Cleaning Strategies 1. NarMind™ Pro Autonomous System With an industry-leading Dual-Chip Camera Recognition technology, Dual-Chip Computing architecture, and advanced AI Vision algorithms, the Freo Z10 Ultra introduces the NarMind™ Pro Autonomous System that redefines on-floor awareness of a robot vacuum. See more and clean smarter, as the...
PR Newswire
15/04/2025

Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1…

Mechelen, Belgium; April 15, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced the departure of its CFO and COO, Thad Huston, effective as of August 1, 2025.Mr. Huston has decided to leave the company and return to the U.S. for personal and professional reasons. Mr. Huston joined Galapagos NV in 2023...
Nasdaq GlobeNewswire
15/04/2025

Press Release: Sanofi's respiratory pipeline advances with new data in asthma…

Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPDNew phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthmaLunsekimig now targeting chronic rhinosinusitis and COPD in addition to asthmaItepekimab expanding into chronic rhinosinusitis along with COPD and bronchiectasis; phase 3 readouts in COPD in H2 2025 and bronchiectasis in 2026 Paris, April 15, 2025.Sanofi today shared new progress from its...
Nasdaq GlobeNewswire
15/04/2025

Kuros Biosciences reports 82% year over year increase in sales in the first…

Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025 Financial & Operational HighlightsDirect MagnetOs™ sales increased by 79% to USD 28.4 million in Q1 2025 (Q1 2024: USD 15.8 million)Total Medical Device sales rose by 82% to USD 28.8 million (Q1 2024: USD 15.8 million) with monthly revenue surpassing USD 10.0 million for the first timeTotal Group EBITDA...
Nasdaq GlobeNewswire
15/04/2025

FDA Approval of Amgen's UPLIZNA for IgG4-related Disease Opens New Market…

Due to its relatively recent identification, lack of widespread clinical awareness, and often subtle or slow-developing symptoms, IgG4-RD is likely underdiagnosed and underreported. It occurs more frequently in men, with most diagnoses in adults between their 30s and 50s, though cases have also been documented in children. In 2024, there were ~149K diagnosed prevalent cases of IgG4-RD across the 7MM, with the United States representing the largest share of these cases. Due to its relatively...
PR Newswire
14/04/2025

Voting Rights and Shares Capital of the Company

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, April14, 2025(GLOBE NEWSWIRE) --Market: Euronext Paris / Nasdaq Euronext Compartment: BISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website:www.nanobiotix.comDate Number of Shares OutstandingTotal number of voting rightsTotal voting...
Nasdaq GlobeNewswire
14/04/2025

IBA – ACQUISITION OF OWN SHARES

Immediate Release – April 14 th, 2025 Louvain-la-Neuve, Belgium, April 14 th, 2025 -In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24 th, 2025. Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the...
Nasdaq GlobeNewswire
14/04/2025

AB Science receives notice of allowance for Unites States patent covering…

PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL DISEASE Paris, April 14, 2025, 6pm CETAB Science SA(Euronext - FR0010557264 - AB) today announced that the United States Patent Office has issued a Notice of Allowance for a patent relating to methods of treating sickle cell disease (i.e. a medical use patent) with its lead compound masitinib, based on preclinical data. This new US patent...
Nasdaq GlobeNewswire
14/04/2025
Altri  Comunicati